Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
Kenneth Cusi, Naveed Sattar, L.E. García-Pérez, et al.
Diabetic Medicine (2018) Vol. 35, Iss. 10, pp. 1434-1439
Closed Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 348
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
Mark L. Hartman, Arun J. Sanyal, Rohit Loomba, et al.
Diabetes Care (2020) Vol. 43, Iss. 6, pp. 1352-1355
Open Access | Times Cited: 266
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 214
Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management
Thomas Marjot, Ahmad Moolla, Jeremy Cobbold, et al.
Endocrine Reviews (2019) Vol. 41, Iss. 1, pp. 66-117
Open Access | Times Cited: 190
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
Mohammad Shafi Kuchay, Sonal Krishan, Sunil Kumar Mishra, et al.
Diabetologia (2020) Vol. 63, Iss. 11, pp. 2434-2445
Open Access | Times Cited: 165
Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
Rong Li, Junyan Zou, Wei Ran, et al.
Frontiers in Endocrinology (2023) Vol. 13
Open Access | Times Cited: 141
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
Riccardo Nevola, Raffaella Epifani, Simona Imbriani, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1703-1703
Open Access | Times Cited: 120
The Emerging Role of Glucagon-like Peptide-1 Receptor Agonists for the Management of NAFLD
Chandani Patel Chavez, Kenneth Cusi, Sushma Kadiyala
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 1, pp. 29-38
Open Access | Times Cited: 116
Hepatic glucose metabolism in the steatotic liver
Egeria Scoditti, Silvia Sabatini, Fabrizia Carli, et al.
Nature Reviews Gastroenterology & Hepatology (2024) Vol. 21, Iss. 5, pp. 319-334
Closed Access | Times Cited: 29
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
André Scheen
Diabetes & Metabolism (2019) Vol. 45, Iss. 3, pp. 213-223
Closed Access | Times Cited: 123
Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
Golnaz Ranjbar, Dimitri P. Mikhailidis, Amirhossein Sahebkar
Metabolism (2019) Vol. 101, pp. 154001-154001
Closed Access | Times Cited: 93
Metabolic-Associated Fatty Liver Disease (MAFLD), Diabetes, and Cardiovascular Disease: Associations with Fructose Metabolism and Gut Microbiota
Karolina Drożdż, Katarzyna Nabrdalik, Weronika Hajzler, et al.
Nutrients (2021) Vol. 14, Iss. 1, pp. 103-103
Open Access | Times Cited: 71
NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations
David Niederseer, Bernhard Wernly, Elmar Aigner, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 3, pp. 467-467
Open Access | Times Cited: 58
Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence
Emir Muzurović, Špela Volčanšek, Karin Zibar, et al.
Journal of Cardiovascular Pharmacology and Therapeutics (2022) Vol. 27
Open Access | Times Cited: 49
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, et al.
Trends in Endocrinology and Metabolism (2022) Vol. 33, Iss. 6, pp. 424-442
Closed Access | Times Cited: 43
Gut–Liver–Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies
Giada Marroncini, Laura Naldi, Serena Martinelli, et al.
Biomedicines (2024) Vol. 12, Iss. 7, pp. 1398-1398
Open Access | Times Cited: 7
Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
Yoshio Sumida, Masashi Yoneda, Katsutoshi Tokushige, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 6, pp. 1907-1907
Open Access | Times Cited: 59
Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
Kyung‐Soo Kim, Byung‐Wan Lee
Clinical and Molecular Hepatology (2020) Vol. 26, Iss. 4, pp. 430-443
Open Access | Times Cited: 55
Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
Gianluca Svegliati‐Baroni, Bárbara G. Patrício, Gessica Lioci, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5820-5820
Open Access | Times Cited: 53
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review
Xiaodan Lv, Yongqiang Dong, Lingling Hu, et al.
Endocrinology Diabetes & Metabolism (2020) Vol. 3, Iss. 3
Open Access | Times Cited: 51
Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease
Jeffrey Budd, Kenneth Cusi
Current Diabetes Reports (2020) Vol. 20, Iss. 11
Closed Access | Times Cited: 51
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
V. A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi
Biomedicines (2022) Vol. 10, Iss. 2, pp. 274-274
Open Access | Times Cited: 36
The metabolic triad of non‐alcoholic fatty liver disease, visceral adiposity and type 2 diabetes: Implications for treatment
Bertrand Cariou
Diabetes Obesity and Metabolism (2022) Vol. 24, Iss. S2, pp. 15-27
Closed Access | Times Cited: 31
Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
Kenneth Cusi
Hepatology (2019) Vol. 69, Iss. 6, pp. 2318-2322
Closed Access | Times Cited: 46
Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real‐world data analysis
Santo Colosimo, Federico Ravaioli, Maria Letizia Petroni, et al.
Liver International (2021) Vol. 41, Iss. 4, pp. 731-742
Open Access | Times Cited: 37
Page 1 - Next Page

Scroll to top